Immunic, Inc.
Immunic, Inc. (IMUX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IMUX · as of Jun 9, 2026
Key Statistics
Explore Immunic, Inc. Data
imux stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 12 · Buy rate: 83.3%
The IMUX analyst consensus is Buy, based on ratings from 12 Wall Street analysts over the past 3 months. The average 12-month price target is $14.50, representing +20.23% upside from the current price of $12.06.
Competitors & Peers
imux competitorsIMUX
ACET
ACRV
BMEA
CBUS
LITSStock Performance
Full HistoryAbout Immunic, Inc.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditi…
what is immunic, inc. · imux stock overview · immunic, inc. company profile · who is immunic, inc. ceo · imux NASDAQ · immunic, inc. headquarters · immunic, inc. business segments
About Stock Overview & Key Data
Immunic, Inc. (IMUX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 17, 2014. As of the latest trading session, IMUX stock price is $12.06, with a market capitalization of $119.0M. The stock has returned +39.10% over the past 12 months and +125.84% year-to-date.
According to 12 Wall Street analysts, the consensus rating for Immunic, Inc. stock is Buy, with an average 12-month price target of $14.50. In fiscal year 2025, Immunic, Inc. reported revenue of — and net income of -$97.2M. For detailed data — including Immunic, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Immunic, Inc. (IMUX) stock price is $12.06. The stock is traded on NASDAQ under the ticker symbol IMUX. The 52-week range is $5.06 – $15.77.